RT Journal Article
SR Electronic
T1 Strategies for Biomarker Development in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 423
OP 426
DO 10.3899/jrheum.111240
VO 39
IS 2
A1 CHRISTOPHER T. RITCHLIN
YR 2012
UL http://www.jrheum.org/content/39/2/423.abstract
AB Psoriatic disease includes psoriasis and associated comorbidities (arthritis, uveitis, inflammatory bowel disease, cardiovascular disease, metabolic syndrome, and anxiety/depression) and is remarkably diverse in disease presentation and course. The marked heterogeneity of musculoskeletal involvement in psoriatic arthritis (PsA) presents major challenges to clinicians regarding diagnosis, risk stratification, and management. Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have begun collaborative efforts to develop biomarkers that can assist in the diagnosis and management of patients with psoriasis and related comorbidities. This brief review provides a rationale for biomarker research in PsA, consideration of types and sources of biomarkers, and examples of important biomarker studies in PsA, followed by a review of trial designs for biomarker research and a discussion of potential funding sources.